John M. Rothman

Corporate Officer/Principal at TYME TECHNOLOGIES, INC.

75 year

Health Technology

Consumer Services

Profile

John M.
Rothman is currently the Executive Vice President-Product Development at Tyme Technologies, Inc. He previously worked as the EVP-Clinical & Scientific Operations at Advaxis, Inc. from 2011 to 2013.
He also worked as the Chief Scientific Officer at Race Oncology Ltd.
Dr. Rothman earned a doctorate degree from Tulane University School of Medicine.

John M. Rothman active positions

Companies	Position	Start
TYME TECHNOLOGIES, INC.	Corporate Officer/Principal	2020-08-18

All active positions of John M. Rothman

Former positions of John M. Rothman

Companies	Position	End
RACE ONCOLOGY LIMITED	Chief Tech/Sci/R&D Officer	2019-09-30
AYALA PHARMACEUTICALS, INC.	Chief Operating Officer	2011-12-08

See the detail of John M. Rothman's experience

Training of John M. Rothman

Tulane University School of Medicine

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John M. Rothman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
RACE ONCOLOGY LIMITED	Health Technology

Private companies	2
Tyme Technologies, Inc. Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.	Health Technology
Advaxis, Inc. Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.	Health Technology

Private companies